Details of the Drug Reposition | DrugMAP

General Information of This Drug (ID: DMAZHT0)

Drug Name	TA-8995 DMAZHT0
Synonyms	Obicetrapib; UNII-8O74K609HN; 8O74K609HN; 866399-87-3; Obicetrapib [INN]; CHEMBL3785197; SCHEMBL17002081; AMG-899; DEZ-001; Obicetrapib (AMG-899 TA-8995); AKOS032954130; HY-18778; 4-((2-(((3,5-Bis(trifluoromethyl)phenyl)methyl)((2R,4S)-1- (ethoxycarbonyl)-2-ethyl-6-(trifluoromethyl)-1,2,3,4- tetrahydroquinolin-4-yl)amino)pyrimidin-5-yl)oxy)butanoic acid; 1(2H)-Quinolinecarboxylic acid, 4-(((3,5-bis(trifluoromethyl)phenyl)methyl)(5-(3-carboxypropoxy)-2-pyrimidinyl)amino)-2-ethyl-3,4-dihydro-6-(trifluoromethyl)-,
Structure
Structure	3D MOL is unavailable			2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)

2 Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Hyperlipidaemia	DIS4R2OG	5C80	Phase 2	[1]
Cardiovascular disease	DIS2IQDX	BA00-BE2Z	Phase 2	[2]
------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT01970215) TA-8995: Its Use in Patients With Mild Dyslipidaemia (TULIP). U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)